MedTrace Logo

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

NCT03592121 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-03-12

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.

Conditions

  • Sexual Dysfunction
  • Sexual Arousal Disorder
  • Sexual Dysfunction, Physiological
  • Breast Cancer
  • Nipple Disorder
  • Neuropathy
  • Cancer of Breast

Interventions

DRUG

AB-101

Apply approximately 1 hour prior to sexual activity

DRUG

Placebo

Apply approximately 1 hour prior to sexual activity

Sponsors & Collaborators

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Krychman, MD · Southern CA Center for Sexual Health and Survivorship Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-09
Primary Completion
2019-10-12
Completion
2019-10-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03592121 on ClinicalTrials.gov